OrbusNeich Medical Group Holdings Limited announced that on September 25, 2023, the Group and Cardiovascular Systems, Inc. entered into an amendment to distribution agreement pursuant to which both parties agreed the term of the Group's appointment of CSI as the exclusive distributor of coronary and peripheral balloon products of the Group in the territory of the United States of America will be extended until December 31, 2027. CSI is a medical device company that develops and commercializes products for the treatment of peripheral and coronary vascular disease. CSI's products include peripheral orbital atherectomy systems, coronary orbital atherectomy systems, crowns, and accessories.

It markets its products through its direct sales force in the United States of America to hospitals and clinics. CSI is headquartered in St. Paul, Minnesota, the United States of America.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, CSI and its ultimate beneficial owner are third parties independent of the Company and of connected persons (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) of the Company.